Allogeneic bone marrow transplantation

Active Ingredient: Sargramostim

Indication for Sargramostim

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Therapeutic intent: Curative procedure

Sargramostim is indicated for the acceleration of myeloid reconstitution in adult and pediatric patients 2 years of age and older undergoing allogeneic bone marrow transplantation from HLA-matched related donors.

For this indication, competent medicine agencies globally authorize below treatments:

250 ug/m²/day administered intravenously over a 2-hour period for three consecutive days until ANC>500 cells/mm³

For:

Dosage regimens

Intravenous, 250 micrograms sargramostim per square meter of body surface, once daily, over the duration of 3 days.

Detailed description

The recommended dose is 250 mcg/m²/day administered intravenously over a 2-hour period beginning two to four hours after bone marrow infusion, and not less than 24 hours after the last dose of chemotherapy or radiotherapy. Do not administer sargramostim until the post marrow infusion ANC is less than 500 cells/mm³. Continue sargramostim until an ANC greater than 1500 cells/mm³ for three consecutive days is attained. Do not administer sargramostim within 24 hours preceding or following receipt of chemotherapy or radiotherapy.

Dose Modifications

Obtain a CBC with differential twice per week during LEUKINE therapy and modify the dose as for the following:

Disease progression or blast cell appearance: Discontinue LEUKINE immediately
Grade 3 or 4 adverse reactions: Reduce the dose of LEUKINE by 50% or temporarily discontinue until the reaction abates
WBC greater than 50,000 cells/mm³ or ANC greater than 20,000 cells/mm³: Interrupt LEUKINE treatment or reduce the dose by 50%

Active ingredient

Sargramostim
Sargramostim is a recombinant human GM-CSF. The binding to GM-CSF receptors expressed on the surface of target cells (haematopoietic progenitors and mature immune cells), initiates an intracellular signalling cascade which induces the cellular responses (i.e., division, maturation, activation). GM-CSF is a multilineage factor and, in addition to dose-dependent effects on the myelomonocytic lineage, it can promote the proliferation and maturation of megakaryocytic and erythroid progenitors. Read more about Sargramostim

Related medicines

Summary of Product Characteristics (SPC) 2025: IMREPLYS Powder for solution for injection

Structured Product Labeling (SPL/PLR) 2024: LEUKINE Powder for solution for injection

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.